Therapy News and Research

RSS

Patients treated with ACEIs and ARBs may be at increased risk of severe COVID-19

James Diaz, MD, MHA, MPH & TM, Dr PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has proposed a possible explanation for the severe lung complications being seen in some people diagnosed with COVID-19.

23 Mar 2020

Using 'young NK cells' could improve the effectiveness of immunotherapy for cancer patients

Immunotherapy that involves treating cancer with the body's own immune cells, or those of a matched donor, shows promise in clinical trials for some patients, but not all.

22 Mar 2020

Coronavirus threatens the lives of rural hospitals already stretched to breaking point

Rural hospitals may not be able to keep their doors open as the coronavirus pandemic saps their cash, their CEOs warn, just as communities most need them.

22 Mar 2020

UC San Diego partners with five leading diagnostics manufacturers to ramp up testing for COVID-19

Partnering with five leading in vitro diagnostics manufacturers, an interdisciplinary team of scientists and physicians at UC San Diego Health and University of California San Diego School of Medicine today announced that the UC San Diego Center for Advanced Laboratory Medicine is significantly ramping up testing for COVID-19, projecting a capacity to complete 1,000 to 1,500 tests per day within two to three weeks.

22 Mar 2020

A review of the literature on acute promyelocytic leukemia

Oncotarget Volume 11, Issue 11 reported that relapsed APL, particularly in the high-risk subset of patients, remains an important clinical problem.

22 Mar 2020

Plasma monitoring of EGFR mutations in NSCLC may help predict resistance to tyrosine kinase inhibitors

Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly monitored during the first month of therapy.

22 Mar 2020

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.

21 Mar 2020

Older cancer patients taking multiple medications are at higher risk of hospitalization

As adults age, they accumulate a number of medications for chronic conditions. Older patients take anywhere between 5-15 medications per year, which increases the risk that some of the drugs will counteract each other.

21 Mar 2020

MILabs enhances preclinical diagnostic U-CT system for COVID-19 research

Based on recent scientific research, diagnostic X-ray CT is able to detect COVID-19, the disease caused by the novel coronavirus (SARS-CoV-2), in individuals with high clinical suspicion of the virus -- even in cases with negative initial DNA tests.

20 Mar 2020

AI may help predict tumor sensitivity to systemic cancer therapies

Using standard-of-care computed tomography scans in patients with advanced non-small cell lung cancer, researchers utilized artificial intelligence to train algorithms to predict tumor sensitivity to three systemic cancer therapies.

20 Mar 2020

CARB-X awards $2.86M to develop novel oral antibiotic to treat drug-resistant gonorrhea

Up to $2.86M has been awarded to a research team including Penn State scientists to develop a new oral antibiotic to treat multidrug-resistant gonorrhea, a sexually transmitted disease caused by bacteria that have developed resistance to all but one existing antibiotic.

20 Mar 2020

How Ritalin works: focus on benefits rather than costs of work

A new study published in the journal Science shows that brain stimulant drugs like Ritalin, often used to treat concentration problems in conditions like attention deficit hyperactivity disorder (ADHD), work in a different way than commonly thought.

19 Mar 2020

Lopinavir and ritonavir drug combo tested in severe COVID-19

Researchers from China and the United Kingdom have collaborated to conduct a clinical trial looking at the efficacy of a combination of two anti-HIV drugs lopinavir and ritonavir to combat severe cases of COVID-19. Their study titled, “A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19,” was published in the latest issue of the New England Journal of Medicine (NEJM).

19 Mar 2020

Research aimed at increasing shelf life of radiation drugs offers hope for cancer patients

People with hard-to-reach cancers in the kidney, gut and prostate will have improved hope for early diagnosis and treatment with new research aimed at increasing the shelf life of revolutionary radiation drugs.

19 Mar 2020

Novel MRI contrast agent for early detection of brain metastases

A group of researchers led by Leif Schroeder from the Leibniz-Forschungsinstitut fuer Molekulare Pharmakologie have found a way to detect metastases in certain types of cancer in the brain at an early stage, using only minimal amounts of contrast agent.

19 Mar 2020

Revolutionary technology could help identify more effective cancer drug combinations

A revolutionary new technology has been applied to reveal the inner workings of individual cancer cells - potentially identifying more effective treatment combinations for people with cancer.

19 Mar 2020

Study helps predict which ovarian cancer patients will not benefit from immune-PARP combo

In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven't been able to predict which patients won't benefit from the treatment and should explore other options.

19 Mar 2020

Study paves way for identifying ovarian cancer patients who will not benefit from combination therapy

A study suggests it may be possible to identify those who will not benefit from drug combination for advanced ovarian cancer.

19 Mar 2020

First-of-its kind study identifies the hidden costs of avoidable deficiencies in heart failure

Today, the first investigation of its kind, published in Open Heart, has identified the hidden costs of heart failure (HF) due to under-managed but treatable iron deficiency (ID) and iron deficiency anaemia (IDA). Leading UK clinicians assessed the one-year data of around 80,000 people with HF as part of the analysis.

19 Mar 2020

Statins may protect against heart damage caused by breast cancer therapies

Statins are widely used to lower cholesterol and prevent heart disease and related deaths, but can they also help guard against heart damage caused by certain breast cancer therapies?

19 Mar 2020

Therapy News and Research

Patients treated with ACEIs and ARBs may be at increased risk of severe COVID-19

Using 'young NK cells' could improve the effectiveness of immunotherapy for cancer patients

Coronavirus threatens the lives of rural hospitals already stretched to breaking point

UC San Diego partners with five leading diagnostics manufacturers to ramp up testing for COVID-19

A review of the literature on acute promyelocytic leukemia

Plasma monitoring of EGFR mutations in NSCLC may help predict resistance to tyrosine kinase inhibitors

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Older cancer patients taking multiple medications are at higher risk of hospitalization

MILabs enhances preclinical diagnostic U-CT system for COVID-19 research

AI may help predict tumor sensitivity to systemic cancer therapies

CARB-X awards $2.86M to develop novel oral antibiotic to treat drug-resistant gonorrhea

How Ritalin works: focus on benefits rather than costs of work

Lopinavir and ritonavir drug combo tested in severe COVID-19

Research aimed at increasing shelf life of radiation drugs offers hope for cancer patients

Novel MRI contrast agent for early detection of brain metastases

Revolutionary technology could help identify more effective cancer drug combinations

Study helps predict which ovarian cancer patients will not benefit from immune-PARP combo

Study paves way for identifying ovarian cancer patients who will not benefit from combination therapy

First-of-its kind study identifies the hidden costs of avoidable deficiencies in heart failure

Statins may protect against heart damage caused by breast cancer therapies

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News